ARTICLE | Clinical News
Invega Sustenna regulatory update
December 14, 2009 8:00 AM UTC
Johnson & Johnson submitted an MAA to EMEA for paliperidone palmitate to treat schizophrenia. The once-monthly intramuscular injection is a long-acting therapy (LAT) formulation of J&J's Invega palipe...